Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oric Pharmaceuticals Inc (NQ: ORIC ) 11.26 +0.57 (+5.33%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Oric Pharmaceuticals Inc < Previous 1 2 Next > ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer July 16, 2024 From ORIC Pharmaceuticals Via GlobeNewswire Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors July 09, 2024 From Attovia Therapeutics, Inc. Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) July 05, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) is a Stock Spotlight on 3/1 March 01, 2024 Via Investor Brand Network ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences May 29, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates May 06, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC April 15, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting April 08, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences April 04, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates March 11, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference March 06, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting March 05, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 01, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit February 14, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences January 31, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Announces $125 Million Private Placement Financing January 22, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones January 08, 2024 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From ORIC Pharmaceuticals Via GlobeNewswire Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development December 11, 2023 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) December 01, 2023 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences November 09, 2023 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates November 06, 2023 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 03, 2023 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting November 02, 2023 From ORIC Pharmaceuticals Via GlobeNewswire Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile October 21, 2023 From ORIC Pharmaceuticals Via GlobeNewswire ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023 October 17, 2023 Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers From ORIC Pharmaceuticals Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.